EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BIO-Europe Spring EBD Group BIO BIO-Europe Spring

Share/Follow Us

Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

BIO-Europe Spring® 2016 Press Releases

July 30, 2014Spotlight on Stockholm/Uppsala Region Business Facts The Stockholm-Uppsala region, defined as the three counties of Uppsala, Stockholm and Sörmland, is one of the largest life science clusters in Europe. Stockholm-Uppsala region is Scandinavia's leading life science cluster and one of the world's most productive, and is one of the most competitive business environments in Europe. On average, an astounding 15–20 new...  more ►



partnering360:Insight Latest headlines from partnering360:Insight

July 21, 2015 Patient-centric Baxalta capitalizes on Cambridge When Baxalta Incorporated spun out of Baxter on July 1, it already qualified as "big pharma." With USD 6 billion in annual revenues, 16,000 employees, operations in 100 countries and USD 600 million invested in R&D, it focuses its assets tightly on the patient experience and expects its partners to do the same. more ►

June 12, 2015 Boehringer Ingelheim Pharmaceuticals: “The world is our laboratory” At Boehringer Ingelheim, “innovation is the element that defines us,” said Paola Casarosa, PhD, Corporate VP, Business Development and Licensing (BD&L)/Prescription Medicines. Its track record bears that out. Boehringer Ingelheim has a 125-year history of innovation that is based not only on its own discoveries but also upon novel finds from partners throughout the life sciences. more ►

June 11, 2015 Boston Children’s Hospital: Innovating from bench to bedside Translating innovation from the bench to the bedside is integral to the mission of Boston Children’s Hospital. Research runs the gamut from biotech and pharmaceutical development to devices, diagnostics and healthcare IT, and is led by researchers who often are appointed not just to Boston Children’s Hospital, but also to prestigious institutions in the area. more ►

June 3, 2015 Agilis builds value by tapping into Boston’s biotech ecosystem In November 2014, Gregory Robinson was named the Chief Scientific Officer for Agilis Biotherapeutics, a biotechnology company engineering best-in-class DNA therapeutics for patients afflicted with devastating rare diseases of the central nervous system (CNS). Formerly the Senior Director for Rare Diseases Business Development and the Head of Discovery Research at Shire, Robinson has stepped up to the challenge of advancing Agilis’ drug and therapy discovery programs. more ►

June 3, 2015 When de-risking, relationships matter De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata. “In the ‘old’ days, you’d look for others working with the same mechanism or against the same targets and hope their data lent confidence to your own investigations as you followed in their wake,” says Richard Brudnick senior VP, corporate development, Biogen, says. That approach reduced risk, but didn’t encourage great innovation. more ►



Arrow Up


 
 

Follow this event: Follow us on Twitter
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2015 EBD GmbH
Privacy Policy and Cookies
Terms of Use